Supernus Pharmaceuticals

Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system disorders. The Company launched Oxtellar XR and Trokendi XR, two novel neurology products for the treatment of epilepsy.  Supernus Pharmaceuticals is also developing several product candidates in psychiatry to address unmet medical needs and opportunities in attention-deficit hyperactivity disorder and its coexisting disorders, and depression.

Company Growth (employees)
Type
Public
HQ
Rockville, US
Founded
2005
Size (employees)
363 (est)+6%
Supernus Pharmaceuticals was founded in 2005 and is headquartered in Rockville, US

Key People at Supernus Pharmaceuticals

Jack Khattar

Jack Khattar

President and CEO

Supernus Pharmaceuticals Office Locations

Supernus Pharmaceuticals has an office in Rockville
Rockville, US (HQ)
1550 E Gude Dr

Supernus Pharmaceuticals Data and Metrics

Supernus Pharmaceuticals Financial Metrics

Supernus Pharmaceuticals's revenue was reported to be $215 m in 2016
Numbers are in $, USD

Revenue (Y, 2016)

215 m

Revenue growth (Y, 2015 - Y, 2016), %

49%

Gross profit (Y, 2016)

203 m

Gross profit margin (Y, 2016), %

94%

Net income (Y, 2016)

91.2 m

EBIT (Y, 2016)

54.2 m

Market capitalization (21-Jun-2017)

2.2 b

Closing share price (21-Jun-2017)

41.4

Cash (31-Dec-2016)

66.4 m
Supernus Pharmaceuticals's current market capitalization is $2.2 b.
FY, 2013FY, 2014FY, 2015Y, 2016

Revenue

12 m122 m144.4 m215 m

Revenue growth, %

915%18%49%

Cost of goods sold

1.1 m5.8 m8.4 m12 m

Gross profit

10.9 m116.3 m136 m203 m

Gross profit Margin, %

91%95%94%94%

Operating expense total

72.8 m92.1 m118.3 m160.8 m

EBIT

(61.9 m)24.2 m17.7 m54.2 m

EBIT margin, %

(515%)20%12%25%

Interest expense

7.8 m5 m1.2 m543 k

Interest income

299 k348 k643 k1.5 m

Income tax expense

956 k(40.9 m)

Net Income

(92.3 m)19.9 m14 m91.2 m
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

33 m36.4 m34.2 m66.4 m

Accounts Receivable

5.1 m17.3 m25.9 m41.5 m

Inventories

7.2 m3.8 m5.3 m3 m

Current Assets

97.2 m108.9 m106 m151.4 m

PP&E

2.6 m2.4 m3.9 m4.3 m

Total Assets

111 m137.5 m188.7 m309.6 m

Accounts Payable

18.3 m1.9 m4.3 m8.1 m

Current Liabilities

26.4 m27.5 m56.1 m80.7 m

Additional Paid-in Capital

212 m230.1 m264 m276.1 m

Retained Earnings

(178.5 m)(158.7 m)(144.6 m)(84.3 m)

Total Equity

33.5 m71.4 m118.9 m191.8 m

Financial Leverage

3.3 x1.9 x1.6 x1.6 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(92.3 m)19.9 m14 m91.2 m

Depreciation and Amortization

742 k928 k921 k2.4 m

Accounts Receivable

(5 m)(12 m)(8.6 m)(16 m)

Inventories

(6 m)(6.3 m)854 k(4.2 m)

Accounts Payable

8.5 m(1.3 m)2.1 m3.5 m

Cash From Operating Activities

(57.9 m)7.7 m32.1 m66.8 m

Purchases of PP&E

(2.1 m)(1.6 m)

Cash From Investing Activities

(12.1 m)(4.9 m)(36.2 m)(36 m)

Cash From Financing Activities

62.7 m570 k1.9 m2.1 m

Interest Paid

2.9 m825 k493 k
Y, 2016

Financial Leverage

1.6 x

Supernus Pharmaceuticals Market Value History

Supernus Pharmaceuticals Company Life and Culture

You may also be interested in